Silvana Santos Meyrelles

Dr. Silvana Santos Meyrelles

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ATAlyne Mendonça Marques Ton
Alyne Mendonça Marques Ton
BCBianca Prandi Campagnaro
Bianca Prandi Campagnaro
GAGisela Aleixo Alves
Gisela Aleixo Alves
RARafaela Aires
Rafaela Aires
LCLarissa Zambom Côco
Larissa Zambom Côco
Elisardo C VasquezElisardo C Vasquez
Elisardo C Vasquez
Background. Alzheimer’s disease (AD) is the most common cause of dementia in elderly patients. Recently, several studies have shown that inflammation and oxidative stress precede the cardinal neuropathological manifestations of AD. In view of the proven antioxidant effects of probiotics, we proposed that continuous dietary supplementation with milk fermented with kefir grains might improve cognitive and metabolic and/or cellular disorders in the AD patients. Methods. This study was designed as an uncontrolled clinical investigation to test the effects of probiotic-fermented milk supplementation (2 mL/kg/daily) for 90 days in AD patients exhibiting cognitive deficit. Cognitive assessment, cytokine expression, systemic oxidative stress levels, and blood cell damage biomarkers were evaluated before (T0) and after (T90) kefir synbiotic supplementation. Results. When the patients were challenged to solve 8 classical tests, the majority exhibit a marked improvement in memory, visual-spatial/abstraction abilities, and executive/language functions. At the end of the treatment, the cytometric analysis showed an absolute/relative decrease in several cytokine markers of inflammation and oxidative stress markers (⋅O2–, H2O2, and ONOO−, ~30%) accompanied by an increase in NO bioavailability (100%). In agreement with the above findings by using the same technique, we observed in a similar magnitude an improvement of serum protein oxidation, mitochondrial dysfunction, DNA damage/repair, and apoptosis. Conclusion. In conclusion, we demonstrated that kefir improves cognitive deficits, which seems to be linked with three important factors of the AD—systemic inflammation, oxidative stress, and blood cell damage—and may be a promising adjuvant therapy against the AD progression.

20 November 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
Thiago PereiraThiago Pereira
Thiago Pereira
LCLarissa Z. Côco
Larissa Z. Côco
ATAlyne M. M. Ton
Alyne M. M. Ton
SMSilvana Santos Meyrelles
Silvana Santos Meyrelles
Manuel Campos-ToimilManuel Campos-Toimil
Manuel Campos-Toimil
Elisardo C VasquezElisardo C Vasquez
Elisardo C Vasquez
The fact that millions of people worldwide suffer from Alzheimer’s disease (AD) or Parkinson’s disease (PD), the two most prevalent neurodegenerative diseases (NDs), has been a permanent challenge to science. New tools were developed over the past two decades and were immediately incorporated into routines in many laboratories, but the most valuable scientific contribution was the “waking up” of the gut microbiota. Disturbances in the gut microbiota, such as an imbalance in the beneficial/pathogenic effects and a decrease in diversity, can result in the passage of undesired chemicals and cells to the systemic circulation. Recently, the potential effect of probiotics on restoring/preserving the microbiota was also evaluated regarding important metabolite and vitamin production, pathogen exclusion, immune system maturation, and intestinal mucosal barrier integrity. Therefore, the focus of the present review is to discuss the available data and conclude what has been accomplished over the past two decades. This perspective fosters program development of the next steps that are necessary to obtain confirmation through clinical trials on the magnitude of the effects of kefir in large samples.

1 December 2021 in Experimental Gerontology
Verified
Journal Article
Closed access
RAR. Aires
R. Aires
MPM.L. Porto
M.L. Porto
LAL.M. de Assis
L.M. de Assis
PPP.A.N. Pereira
P.A.N. Pereira
GCG.R. Carvalho
G.R. Carvalho
SMSilvana Santos Meyrelles
Silvana Santos Meyrelles

4 January 2022 in Food & Function
Verified
Journal Article
Closed access
PDF file
RARafaela Aires
Rafaela Aires
FAFernanda Gobbi Amorim
Fernanda Gobbi Amorim
LCLarissa Zambom Côco
Larissa Zambom Côco
ACAmanda Pompermayer da Conceição
Amanda Pompermayer da Conceição
TZTadeu Ériton Caliman Zanardo
Tadeu Ériton Caliman Zanardo
SMSilvana Santos Meyrelles
Silvana Santos Meyrelles
The benefits of kefir consumption are partially due to the rich composition of bioactive molecules released from its fermentation. Angiotensin-converting enzyme (ACE) inhibitors are bioactive molecules with potential use in the treatment or prevention of hypertension, heart failure, and myocardial infarction. Here, the in vivo actions of the Kef-1 peptide, an ACE inhibitor derived from kefir, were evaluated in an angiotensin II-dependent hypertension model. The Kef-1 peptide showed a potential anti-hypertensive effect. Additionally, Kef-1 exhibited systemic antioxidant and anti-inflammatory activities. In smooth muscle cells (SMCs), the Kef-1 peptide decreased ROS production through the reduced participation of NADPH oxidase and mitochondria. The aorta of 2K1C mice treated with Kef-1 showed lesser wall-thickening and partial restoration of the endothelial structure. In conclusion, these novel findings highlight the in vivo biological potential of this peptide demonstrating that Kef-1 may be a relevant nutraceutical treatment for cardiovascular diseases.

26 November 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
LBLarissa Trarbach Figueiredo Braga
Larissa Trarbach Figueiredo Braga
IRIsadora Martins Ribeiro
Isadora Martins Ribeiro
MBMaria Eduarda de Souza Barroso
Maria Eduarda de Souza Barroso
EKEdgar Hell Kampke
Edgar Hell Kampke
LNLorena Nascimento Nascimento Santos Neves
Lorena Nascimento Nascimento Santos Neves
SMSilvana Santos Meyrelles
Silvana Santos Meyrelles
Periodontitis, an oral disease initiated by a dysbiotic dental biofilm, has an unclear response to photobiomodulation (PBM) as an adjunctive treatment. This study investigates the effects of PBM on reactive oxygen species (ROS), apoptosis, oxidative stress, and inflammatory markers in a periodontitis model using C57BL/6 mice, divided into four groups: control (C), control + PBM (C + PBM), periodontitis (P), and periodontitis + PBM (P + PBM). An infrared diode laser (808 nm, 133.3 J/cm2, 4 J/session) was applied for three days. PBM reduced superoxide anions, hydrogen peroxide, and apoptosis in gingival cells, while decreasing systemic inflammation and protein oxidation. In the P + PBM group, pro-inflammatory cytokines IL-6 and IL-12p70 decreased, whereas IL-10 increased, suggesting improvements in oxidative stress and inflammation profiles.

10 October 2023 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
IRIsadora Martins Ribeiro
Isadora Martins Ribeiro
MBMaria Eduarda de Souza Barroso
Maria Eduarda de Souza Barroso
EKEdgar Hell Kampke
Edgar Hell Kampke
LBLARISSA TRARBACH FIGUEIREDO BRAGA
LARISSA TRARBACH FIGUEIREDO BRAGA
BCBianca Prandi Campagnaro
Bianca Prandi Campagnaro
SMSilvana Santos Meyrelles
Silvana Santos Meyrelles
Background: Near-infrared irradiation photobiomodulation (NIR-PBM) has been successfully used in periodontal treatment as an adjuvant tool to locally improve cell function and regeneration. Although the relationship between periodontitis and systemic disease constitutes an important aspect of periodontal clinical research, the systemic effects of NIR-PBM in periodontitis are not well known. In this study, we aimed to investigate the effects of NIR-PBM on systemic oxidative stress and inflammation in an apolipoprotein E (ApoE) knockout mouse model of periodontal disease (PD). Methods: We evaluated alveolar bone loss by measuring the distance from the cementoenamel junction (CEJ) to the alveolar bone crest (ABC), reactive oxygen species (ROS) production in blood cells, inflammatory activity, plasma cholesterol levels, and lipid peroxidation levels in three experimental groups: (1) ApoEC, control group without intervention; (2) ApoEP, first molar ligation-induced periodontitis for 4 weeks; and (3) ApoEP + PBM, exposed to 808 nm continuous wave, ø ~ 3 mm2, 100 mW, 60 s of NIR-PBM for 7 consecutive days after 4 weeks of periodontitis. At the end of the experimental protocols, ApoEP mice presented significantly increased alveolar bone loss, ROS production, inflammatory activity, plasma cholesterol, and lipid peroxidation levels compared to the ApoEC group (P < 0.05). NIR-PBM for 7 days in the ApoEP + PBM mice significantly decreased systemic ROS production, inflammatory response, plasma cholesterol, and lipid peroxidation levels, similar to those found in the ApoEC group (P > 0.05). However, it was not capable of preventing alveolar bone loss (P > 0.05 compared to ApoEP mice). Conclusion: A 7-day treatment with NIR-PBM effectively reduces systemic oxidative stress and inflammatory parameters in hypercholesterolemic mice with PD. However, more studies with longer evaluation times are needed to confirm the systemic effects of locally applied NIR-PBM on PD associated with hypercholesterolemia.